TL;DR
This study uncovers a novel epigenetic mechanism driving resistance to melanoma cancer drugs. Haploinsufficiency of the histone deacetylase SIRT6 leads to increased IGFBP2 expression, activating survival pathways and allowing cancer cells to persist under treatment. Combining MAPK inhibitors with IGF-1R inhibitors effectively overcomes this resistance, suggesting a new therapeutic strategy and IGFBP2 as a potential biomarker.
What Problem Does This Paper Address?
Melanoma, a particularly aggressive form of skin cancer, is often treated with targeted therapies that inhibit the BRAF protein (specifically the V600E mutation) and its downstream signaling pathways (MAPK pathway). While these treatments are initially effective for many patients, a significant challenge is the development of drug resistance, leading to disease relapse. Existing research has identified various genetic mutations and alterations contributing to this resistance, but the role of epigenetic regulation – changes in gene expression that don't involve alterations to the underlying DNA sequence – has remained largely unexplored. This paper aims to fill that gap by investigating how epigenetic factors, specifically those related to chromatin modification, contribute to melanoma's ability to resist targeted MAPK inhibitors.
Methods
The researchers employed a comprehensive, multi-pronged approach:
- CRISPR-Cas9 Screening: A genome-wide CRISPR-Cas9 screen was used to systematically knock out genes encoding chromatin regulators in BRAFV600E melanoma cells. This allowed them to identify specific genes whose depletion conferred resistance to MAPK inhibitors (MAPKi).
- Molecular Biology Techniques: Standard molecular biology techniques were used to validate findings, including:
- Immunoblotting (Western Blotting): To detect and quantify protein levels of SIRT6, IGFBP2, and signaling pathway components (e.g., phosphorylated IGF-1R, AKT, MEK, ERK).
- Quantitative RT-PCR (qPCR): To measure mRNA expression levels of specific genes.
- Chromatin Immunoprecipitation Sequencing (ChIP-seq): To map the binding sites of SIRT6 and specific histone modifications (H3K9ac, H3K56ac) across the genome, revealing how SIRT6 interacts with DNA and influences chromatin structure.
- ATAC-sequencing (ATAC-seq): To assess chromatin accessibility, indicating regions of the genome that are open and potentially transcriptionally active.
- Transcriptomic Analysis (RNA-seq): To comprehensively analyze changes in gene expression patterns in response to SIRT6 manipulation and MAPKi treatment.
- Reverse Phase Protein Array (RPPA): A high-throughput method to simultaneously measure the levels of hundreds of proteins and their post-translational modifications.
- In Vitro and In Vivo Models:
- Cell Culture: Various melanoma cell lines, including those engineered for drug resistance or with altered SIRT6 levels, were used for drug sensitivity assays.
- Xenograft Models: Human melanoma cells were implanted into immunocompromised mice to study drug response and tumor growth in a living system.
- Patient Sample Analysis: Immunohistochemistry (IHC) was performed on melanoma tumor samples from patients to correlate IGFBP2 and SIRT6 levels with clinical outcomes and treatment response.
Datasets
- CRISPR-Cas9 Screen Data: Data from the CRISPR-Cas9 screen in SKMel-239 BRAFV600E melanoma cells, identifying genes that confer MAPKi resistance when knocked out.
- RNA-seq Data: Transcriptomic data from control and SIRT6-modified melanoma cells, with and without MAPKi treatment.
- ChIP-seq and ATAC-seq Data: Genomic data mapping SIRT6 binding sites, histone modifications, and chromatin accessibility.
- RPPA Data: Protein expression profiles from melanoma cells.
- Patient Tumor Samples: Matched tumor biopsies from melanoma patients treated with dabrafenib + trametinib, used for IHC analysis of IGFBP2 and SIRT6.
- TCGA Data: Publicly available The Cancer Genome Atlas data for IGFBP2 mRNA and protein expression in melanoma.
Key Insights and Ideas
- SIRT6 as a Gatekeeper of Resistance: The study reveals that haploinsufficiency (having only one functional copy) of SIRT6, a histone deacetylase, is sufficient to induce resistance to MAPK inhibitors. This is a crucial distinction from complete loss of function.
- Epigenetic Control of IGFBP2: SIRT6's role in resistance is mediated by its direct regulation of IGFBP2 expression. SIRT6 normally keeps IGFBP2 expression low by modifying chromatin at its locus. When SIRT6 is reduced, chromatin becomes more accessible, leading to increased IGFBP2.
- IGFBP2 as a Key Mediator: Upregulated IGFBP2 then activates the IGF-1 receptor (IGF-1R) and its downstream AKT signaling pathway. This pathway is known to promote cell survival and is largely independent of the MAPK pathway, explaining how cells can survive MAPKi treatment.
- Dose-Dependent Effect of SIRT6: The study highlights a critical dose-dependent effect: haploinsufficiency of SIRT6 leads to resistance, while complete depletion of SIRT6 actually sensitizes cells to MAPKi, potentially due to increased DNA damage and genomic instability.
- Therapeutic Synergy: Combining a BRAF inhibitor (BRAFi) with an IGF-1R inhibitor (IGF-1Ri) effectively overcomes the resistance phenotype in both in vitro and in vivo models. This suggests a promising new combination therapy.
- IGFBP2 as a Biomarker: Elevated IGFBP2 levels in patient tumors correlate with MAPKi resistance and poorer prognosis, making it a potential predictive biomarker for treatment response.
Key Results
- A CRISPR-Cas9 screen identified SIRT6 as a key regulator of MAPKi resistance.
- SIRT6 haploinsufficiency led to increased IGFBP2 expression, H3K56 acetylation at the IGFBP2 locus, and activation of the IGF-1R/AKT pathway.
- SIRT6 haploinsufficient melanoma cells showed significantly reduced sensitivity to BRAFi and BRAFi + MEKi in vitro and in vivo.
- Complete SIRT6 depletion, in contrast, led to increased sensitivity to MAPKi.
- Combination therapy with BRAFi and an IGF-1Ri significantly reduced tumor growth and increased apoptosis in resistant melanoma models.
- IGFBP2 protein levels were significantly higher in BRAFV600E/K mutant melanomas and correlated with resistance in patient samples.
- IGFBP2 expression was inversely correlated with SIRT6 expression in human melanoma tissues.
- High IGFBP2 expression in primary melanomas was associated with poorer overall survival.
Limitations and Future Work
- Other Resistance Mechanisms: While the study identifies a significant epigenetic mechanism involving SIRT6 and IGFBP2, it acknowledges that other genes and pathways might also contribute to MAPKi resistance. For instance, AEBP1 was also found to be upregulated, but its role is suggested to be downstream of IGF-1R/AKT activation rather than directly regulated by SIRT6.
- Clinical Translation of Combination Therapy: While promising, further clinical trials are needed to validate the efficacy and safety of combining BRAFi with IGF-1Ri in patients with BRAFV600E-mutant melanoma, particularly those predicted to be resistant.
- Understanding SIRT6 Depletion Effects: The study noted that complete SIRT6 depletion leads to increased sensitivity due to genomic instability. Further research could explore the therapeutic potential of inducing this state to sensitize tumors to existing therapies.
- Biomarker Validation: While IGFBP2 shows promise as a biomarker, larger, prospective clinical studies are necessary to fully validate its predictive power for MAPKi resistance.
- Mechanism of IGFBP2 Upregulation: While the study shows SIRT6 regulates IGFBP2, the precise molecular mechanisms by which IGFBP2 influences IGF-1R signaling and promotes survival could be further elucidated.
Summary updated